Role of Interleukin-6 Correlated to C. pneumoniae Infection as a Biomarker for Prediction of Stroke Severity in Young Patients with Acute Ischemic Stroke
Background. Stroke in young is the leading cause of morbidity and mortality in the Indian subcontinent with a reported incidence of 15–30% of all stroke patients. The mechanisms for stroke in the young may include unconventional risk factors such as infections. Causative role of C. pneumoniae infection in patients with acute ischemic stroke (AIS) remains unresolved till date, although the link between C. pneumoniae and cerebrovascular disease has been investigated in many studies. This study examined the upregulation of IL-6 after acute cerebral ischemia and correlated the same with the C. pneumoniae antibody titres (IgG, IgA, and IgM). Methods. We studied blood samples from eighty ( ) acute stroke patients and healthy age- and sex-matched controls. Venous blood samples were drawn within one week from the onset of stroke. Detection of IgA, IgG, and IgM antibodies to C. pneumoniae was done with a validated microimmunofluorescence (MIF) technique from 5？mL of serum in all subjects. Interleukin-6 was estimated with sandwich ELISA method. Results. The IL-6 levels were elevated in patients with a mean 28.9 ± 8.6？pg/mL as compared to 4.7 + 1.8？pg/mL in healthy age-matched controls (95% CI: 37.7 to 78.4; ). On correlation of IL-6 to stroke severity, it was found that 30 patients with NIHSS between 0 and 15 had mean IL-6 of 24.6？pg/mL and 50 patients had NIHSS of 18.8 (severely affected) with a mean IL-6 of 43.8？pg/mL. On multivariate analysis after adjusting for sex, hypertension, diabetes mellitus, smoking, and alcohol, the IgA seropositivity yielded an adjusted OR for stroke (4.72; 95% CI: 1.61, 13.83; ), while IgG seropositivity did not show a statistically significant result. We also observed that 81% of cases were seropositive for IgA versus 32% of controls ( ) followed by IgG, as 52.7% of cases were seropositive versus 17.3% of controls ( ). Multiple regression analysis was done with IL-6 as dependent variable to antibody with IL-6 as dependent variable to Cp-IgA, Cp-IgG, and IgM with 10.4% change in the IL-6 titres showing statistical significant result = 3.32, . Conclusions. IL-6 has important role after acute ischemic stroke and is correlated with stroke severity and may correlate to acute or chronic infectious states with C. pneumonia. 1. Introduction Young stroke patients constitute 15–30% of all stroke patients in India, to that of 3.0–8.5% of all stroke patients reported from the West [1]. Stroke in young, including stroke in children and young adults (<45 years), is an important cause of morbidity throughout the world, especially in developing
References
[1]
P. M. Dalal, “Strokes in young and elderly: risk factors and strategies for stroke prevention,” Journal of Association of Physicians of India, vol. 45, no. 2, pp. 125–131, 1997.
[2]
T. K. Banerjee and S. K. Das, “Epidemiology of stroke in India,” Neurology Asia, vol. 11, pp. 1–4, 2006.
[3]
M. S. V. Elkind, M. L. C. Tondella, D. R. Feikin, B. S. Fields, S. Homma, and M. R. Di Tullio, “Seropositivity to Chlamydia pneumoniae is associated with risk of first ischemic stroke,” Stroke, vol. 37, no. 3, pp. 790–795, 2006.
[4]
J. Abraham, P. S. Rao, S. G. Inbaraj, G. Shetty, and C. J. Jose, “An epidemiological study of hemiplegia due to stroke in South India.,” Stroke, vol. 1, no. 6, pp. 477–481, 1970.
[5]
T. K. Banerjee, C. S. Mukherjee, and A. Sarkhel, “Stroke in the urban population of Calcutta: an epidemiological study,” Neuroepidemiology, vol. 20, no. 3, pp. 201–207, 2001.
[6]
D. Virok, Z. Kis, L. Karai et al., “Chlamydia pneumoniae in atherosclerotic middle cerebral artery,” Stroke, vol. 32, no. 9, pp. 1973–1976, 2001.
[7]
M. V. Kalayoglu, P. Libby, and G. I. Byrne, “Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease,” Journal of the American Medical Association, vol. 288, no. 21, pp. 2724–2731, 2002.
[8]
G. K. Hansson, “Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease,” The New England Journal of Medicine, vol. 352, no. 16, pp. 1626–1695, 2005.
[9]
P. M. Ridker, C. H. Hennekens, J. E. Buring, R. Kundsin, and J. Shih, “Baseline IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women,” Annals of Internal Medicine, vol. 131, no. 8, pp. 573–577, 1999.
[10]
R. Cosentini and F. Blasi, “New pathogens for respiratory infections,” Current Opinion in Pulmonary Medicine, vol. 2, no. 3, pp. 174–180, 1996.
[11]
U. Waje-Andreassen, J. Kr？kenes, E. Ulvestad et al., “IL-6: an early marker for outcome in acute ischemic stroke,” Acta Neurologica Scandinavica, vol. 111, no. 6, pp. 360–365, 2005.
[12]
F. Perini, M. Morra, M. Alecci, E. Galloni, M. Marchi, and V. Toso, “Temporal profile of serum anti-inflammatory and pro-inflammatory interleukins in acute ischemic stroke patients,” Neurological Sciences, vol. 22, no. 4, pp. 289–296, 2001.
[13]
M. A. Mendall, P. M. Goggin, N. Molineaux et al., “Relation of Helicobacter pylori infection and coronary heart disease,” British Heart Journal, vol. 71, no. 5, pp. 437–439, 1994.
[14]
P. J. Cook, D. Honeybourne, G. Y. H. Lip, D. G. Beevers, R. Wise, and P. Davies, “Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia: the West Birmingham stroke project,” Stroke, vol. 29, no. 2, pp. 404–410, 1998.
[15]
M. Leinonen, “Pathogenetic mechanisms and epidemiology of Chlamydia pneumoniae,” European Heart Journal, vol. 14, pp. 57–61, 1993.
[16]
R. Jin, G. Yang, and G. Li, “Inflammatory mechanisms in ischemic stroke: role of inflammatory cells,” Journal of Leukocyte Biology, vol. 87, no. 5, pp. 779–789, 2010.
[17]
N. K. Rai, R. Choudhary, R. Bhatia et al., “Chlamydia pneumoniae seropositivity in adults with acute ischemic stroke: a case-control study,” Annals of Indian Academy of Neurology, vol. 14, no. 2, pp. 93–97, 2011.
[18]
Y. Sonobe, J. Liang, S. Jin et al., “Microglia express a functional receptor for interleukin-23,” Biochemical and Biophysical Research Communications, vol. 370, no. 1, pp. 129–133, 2008.
[19]
B. Becher, B. G. Durell, and R. J. Noelle, “IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis,” Journal of Clinical Investigation, vol. 112, no. 8, pp. 1186–1191, 2003.
[20]
E. H. Lo, “Experimental models, neurovascular mechanisms and translational issues in stroke research,” British Journal of Pharmacology, vol. 153, supplement 1, pp. S396–S405, 2008.
[21]
K. Gertz, G. Kronenberg, R. E. K？lin, et al., “Essential role of interleukin-6 in post-stroke angiogenesis,” Brain, vol. 135, no. 6, pp. 1964–1980, 2012.
[22]
Y. Maeda, M. Matsumoto, O. Hori et al., “Hypoxia/reoxygenation-mediated induction of astrocyte interleukin 6: a paracrine mechanism potentially enhancing neuron survival,” Journal of Experimental Medicine, vol. 180, no. 6, pp. 2297–2308, 1994.
[23]
S. Suzuki, K. Tanaka, S. Nogawa et al., “Temporal profile and cellular localization of interleukin-6 protein after focal cerebral ischemia in rats,” Journal of Cerebral Blood Flow and Metabolism, vol. 19, no. 11, pp. 1256–1262, 1999.
[24]
I. Gueorguieva, S. R. Clark, C. J. McMahon et al., “Pharmacokinetic modeling of interleukin- 1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid hemorrhage,” British Journal of Clinical Pharmacology, vol. 65, no. 3, pp. 317–325, 2008.
[25]
D. Acalovschi, T. Wiest, M. Hartmann et al., “Multiple levels of regulation of the interleukin-6 system in stroke,” Stroke, vol. 34, no. 8, pp. 1864–1869, 2003.
[26]
G. Madre, J. L. Garcia, R. C. Gonzalez et al., “Association between seropositivity to Chlamydia pneumoniae and acute ischaemic stroke,” European Journal of Neurology, vol. 9, no. 3, pp. 303–306, 2002.
[27]
S. L. Melnick, E. Shahar, A. R. Folsom et al., “Past infection by Chlamydia pneumoniae strain and asymptomatic carotid atherosclerosis,” The American Journal of Medicine, vol. 95, no. 5, pp. 499–504, 1993.
[28]
S. L. Stevens, J. Bao, J. Hollis, N. S. Lessov, W. M. Clark, and M. P. Stenzel-Poore, “The use of flow cytometry to evaluate temporal changes in inflammatory cells following focal cerebral ischemia in mice,” Brain Research, vol. 932, no. 1-2, pp. 110–119, 2002.
[29]
D. L. Hahn, T. Anttila, and P. Saikku, “Association of Chlamydia pneumoniae IgA antibodies with recently symptomatic asthma,” Epidemiology and Infection, vol. 117, no. 3, pp. 513–517, 1996.
[30]
C. J. Smith, H. C. A. Emsley, C. M. Gavin et al., “Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome,” BMC Neurology, vol. 4, article 5, 2004.
[31]
M. V. Kalayoglu, P. Libby, and G. I. Byrne, “Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease,” Journal of the American Medical Association, vol. 288, no. 21, pp. 2724–2731, 2002.
[32]
P. Saikku, K. Mattila, M. S. Nieminen et al., “Serological evidence of an association of a novel chlamydia, with chronic coronary heart disease and acute myocardial infarction,” The Lancet, vol. 2, no. 8618, pp. 983–986, 1988.
[33]
S. Pelidou, N. Kostulas, D. Matusevicius, P. Kivis？kk, V. Kostulas, and H. Link, “High levels of IL-10 secreting cells are present in blood in cerebrovascular diseases,” European Journal of Neurology, vol. 6, no. 4, pp. 437–442, 1999.
[34]
V. C. S. S. Bandaru, V. Laxmi, M. Neeraja et al., “Chlamydia pneumoniae antibodies in various subtypes of ischemic stroke in Indian patients,” Journal of the Neurological Sciences, vol. 272, no. 1-2, pp. 115–122, 2008.
[35]
M. S. V. Elkind, I. F. Lin, J. T. Grayston, and R. L. Sacco, “Chlamydia pneumoniae and the risk of first ischemic stroke: the northern manhattan stroke study,” Stroke, vol. 31, no. 7, pp. 1521–1525, 2000.
[36]
E. Tarkowski, L. Rosengren, C. Blomstrand et al., “Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke,” Stroke, vol. 26, no. 8, pp. 1393–1398, 1995.
[37]
J. S. Kim, S. S. Yoon, Y. H. Kim, and J. S. Ryu, “Serial measurement of interleukin-6, transforming growth factor-β, and S-100 protein in patients with acute stroke,” Stroke, vol. 27, no. 9, pp. 1553–1557, 1996.
[38]
W. Whiteley, C. Jackson, S. Lewis et al., “Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6,” PLoS Medicine, vol. 6, no. 9, Article ID e1000145, 2009.
[39]
J. Castillo and I. Rodríguez, “Biochemical changes and inflammatory response as markers for brain ischaemia: molecular markers of diagnostic utility and prognosis in human clinical practice,” Cerebrovascular Diseases, vol. 17, supplement 1, pp. 7–18, 2004.
[40]
N. Vila, J. Castillo, A. Dávalos, A. Esteve, A. M. Planas, and á. Chamorro, “Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke,” Stroke, vol. 34, no. 3, pp. 671–675, 2003.
[41]
P. J. Martin, T. V. Enevoldson, and P. R. Humphrey, “Causes of ischemic stroke in young,” Postgraduate Medical Journal, vol. 73, no. 855, pp. 8–16, 1997.
[42]
G. Yilmaz and D. N. Granger, “Cell adhesion molecules and ischemic stroke,” Neurological Research, vol. 30, no. 8, pp. 783–793, 2008.
[43]
N. Vila, J. Castillo, A. Dávalos, and á. Chamorro, “Proinflammatory cytokines and early neurological worsening in ischemic stroke,” Stroke, vol. 31, no. 10, pp. 2325–2329, 2000.
[44]
J. Ngeh, S. Gupta, C. Goodbourn, B. Panayiotou, and G. McElligott, “Chlamydia pneumoniae in elderly patients with stroke (C-PEPS): a case-control study on the seroprevalence of Chlamydia pneumoniae in elderly patients with acute cerebrovascular disease,” Cerebrovascular Diseases, vol. 15, no. 1-2, pp. 11–16, 2003.
[45]
K. Yamashita, K. Ouchi, M. Shirai, T. Gondo, T. Nakazawa, and H. Ito, “Distribution of Chlamydia pneumoniae infection in the atherosclerotic carotid artery,” Stroke, vol. 29, no. 4, pp. 773–778, 1998.
